We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+9.4%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.38B
AUM Growth
+$319M
(+4%)
Cap. Flow
-$50.3M
Cap. Flow
% of AUM
-0.6%
Top 10 Holdings %
Top 10 Hldgs %
33.94%
Holding
161
New
20
Increased
28
Reduced
35
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
+$304M |
| 2 |
Elevance Health
ELV
|
+$123M |
| 3 |
Dentsply Sirona
XRAY
|
+$102M |
| 4 |
AGN
Allergan plc
AGN
|
+$95.1M |
| 5 |
Inspire Medical Systems
INSP
|
+$78.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$185M |
| 2 |
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
|
+$154M |
| 3 |
AbbVie
ABBV
|
+$145M |
| 4 |
Tenet Healthcare
THC
|
+$119M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$69.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.69% |
| 2 | Financials | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
| $388M | 4.63% |
3,124,603
-143,672
| -4% | -$16.8M |
|
2
Biogen
BIIB
$30.4B
| $339M | 4.04% |
1,167,900
+127,500
| +12% | +$35.8M |
|
|
TCDA
3
DELISTED
Tricida, Inc. Common Stock
TCDA
| $326M | 3.88% |
+10,889,280
| New | +$304M |
|
4
Boston Scientific
BSX
$68.5B
| $313M | 3.73% |
9,574,695
-803,100
| -8% | -$24.2M |
|
5
Vertex Pharmaceuticals
VRTX
$124B
| $305M | 3.63% |
1,792,600
-62,000
| -3% | -$9.61M |
|
6
Ascendis Pharma A/S
ASND
$16.7B
| $294M | 3.5% |
4,413,291
+1,045,976
| +31% | +$68.8M |
|
7
Merck
MRK
$326B
| $284M | 3.39% |
4,904,640
-637,394
| -12% | -$36M |
|
|
AGN
8
DELISTED
Allergan plc
AGN
| $214M | 2.56% |
1,286,205
+592,600
| +85% | +$95.1M |
|
|
CELG
9
DELISTED
Celgene Corp
CELG
| $204M | 2.44% |
2,570,650
-63,600
| -2% | -$5.28M |
|
10
Jazz Pharmaceuticals
JAZZ
$16.1B
| $179M | 2.14% |
1,040,100
| – | – |
|
|
WMGI
11
DELISTED
Wright Medical Group Inc
WMGI
| $164M | 1.96% |
6,322,668
-529,400
| -8% | -$12.1M |
|
12
Puma Biotechnology
PBYI
$406M
| $162M | 1.93% |
2,732,881
+91,220
| +3% | +$5.29M |
|
|
CMTA
13
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| $137M | 1.64% |
10,425,225
| – | – |
|
14
Viatris
VTRS
$20.8B
| $134M | 1.6% |
3,702,800
+1,868,500
| +102% | +$73.3M |
|
|
15
Bristol-Myers Squibb
BMY
$130B
| $132M | 1.57% |
2,380,300
-1,295,000
| -35% | -$69.9M |
|
|
16
Regeneron Pharmaceuticals
REGN
$72.9B
| $129M | 1.53% |
372,500
-590,400
| -61% | -$185M |
|
|
AERI
17
DELISTED
Aerie Pharmaceuticals
AERI
| $127M | 1.52% |
1,884,100
| – | – |
|
18
Edwards Lifesciences
EW
$48.2B
| $127M | 1.51% |
2,612,700
-461,100
| -15% | -$21.5M |
|
|
19
Elevance Health
ELV
$83.7B
| $127M | 1.51% |
+531,800
| New | +$123M |
|
20
Alnylam Pharmaceuticals
ALNY
$38.5B
| $125M | 1.49% |
1,265,966
| – | – |
|
21
Thermo Fisher Scientific
TMO
$214B
| $121M | 1.44% |
583,500
+194,100
| +50% | +$41.2M |
|
22
DaVita
DVA
$15.4B
| $117M | 1.4% |
1,689,400
+129,800
| +8% | +$8.67M |
|
|
IMMU
23
DELISTED
Immunomedics Inc
IMMU
| $117M | 1.4% |
4,944,573
-766,201
| -13% | -$15.4M |
|
24
Agilent Technologies
A
$39.7B
| $117M | 1.39% |
1,885,100
-951,800
| -34% | -$62.1M |
|
|
FOLD
25
DELISTED
Amicus Therapeutics
FOLD
| $110M | 1.32% |
7,072,500
| – | – |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q2 2018 Portfolio in Review
As of Q2 2018, OrbiMed held 161 positions worth $8.38B, up 4% from $8.07B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
OrbiMed's Q2 2018 filing shows 20 new, 28 increased, 35 reduced and 14 closed positions. Its largest new stake was Tricida, Inc. Common Stock: 10,889,280 shares worth $326M. The largest sale was Regeneron Pharmaceuticals, an estimated $185M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier, followed by Financials.
- OrbiMed's largest Q2 2018 buy was Tricida, Inc. Common Stock: 10,889,280 shares worth $326M.
- OrbiMed added most to Dentsply Sirona in Q2 2018, an estimated $102M increase.
- OrbiMed's biggest Q2 2018 reduction was Regeneron Pharmaceuticals, cutting an estimated $185M.
- OrbiMed fully exited ARMO BioSciences, Inc. Common Stock in Q2 2018, selling an estimated $154M.
- OrbiMed's ten largest holdings make up 34% of its $8.38B portfolio in Q2 2018.
- OrbiMed opened 20 new positions and closed 14 in Q2 2018.
- OrbiMed's portfolio value rose 4% quarter-over-quarter to $8.38B.
Based on OrbiMed's 13F filing for Q2 2018, filed 14 Aug 2018.